When Is Mohs Surgery the Right Choice? How the Appropriate Use Criteria Were Built

Mohs micrographic surgery is the right choice when a skin cancer combines a high-risk location, aggressive or poorly defined behavior, or a patient whose immune system cannot afford a recurrence. The 2012 appropriate use criteria (AUC), published in the Journal of the American Academy of Dermatology, turned that clinical instinct into a rated map. An expert panel scored 270 specific tumor-and-patient scenarios and judged Mohs appropriate for 200 of them, uncertain for 24, and inappropriate for 46. The criteria do not dictate what to do in any single case. They describe, scenario by scenario, where the technique's tissue-sparing precision and high cure rate are most likely to justify its cost.

What Mohs surgery actually buys

Mohs surgery removes a skin cancer in stages, mapping and examining essentially the entire surgical margin under the microscope before the wound is closed. That complete margin assessment is why cure rates for previously untreated basal cell carcinoma are commonly reported near 99 percent in long-term follow-up, among the highest of any treatment for these cancers, and why healthy surrounding tissue can be spared rather than sacrificed to a wider guess. The trade-off is genuine. Mohs is slower, costs more, and demands more of the surgeon and the histology lab than a standard excision or a destructive method such as electrodesiccation and curettage.

For a small, low-risk cancer on the trunk, that added precision may deliver little extra benefit over simpler options. For a poorly defined tumor on the eyelid or nasal tip, it can be the difference between a single clean procedure and a disfiguring re-excision. The value of Mohs is not fixed. It rises and falls with the tumor and the patient, which is exactly the problem a rating system had to solve.

Why a rating system was needed

Before the AUC, decisions about who received Mohs varied widely between practices and regions. As the technique spread and its use grew, so did concern about both overuse in low-yield settings and underuse where the evidence was strongest. Reimbursement bodies wanted a defensible way to distinguish the two. Patients wanted to know whether a more involved procedure was warranted for their particular lesion. What existed was a large body of cure-rate and recurrence data but no consistent framework translating that evidence into a decision for the tumor in front of you.

The AUC were built to close that gap. They combine published evidence with structured expert judgment for the many real-world combinations that trials never isolate cleanly, such as a moderately aggressive squamous cell carcinoma on the cheek of an organ-transplant recipient.

How the panel built the criteria

The methodology is adapted from cardiology and radiology, fields that faced the same question of appropriate use. It follows the RAND/UCLA Appropriateness Method, a validated modified Delphi process designed to surface where evidence and experienced judgment converge, and where they do not.

A ratings panel of 17 members did the scoring: 8 Mohs surgeons and 9 dermatologists who do not perform Mohs, drawn from different regions and practice settings so that no single viewpoint dominated. Each member rated every scenario on a 9-point scale. A score of 7 to 9 meant appropriate, 4 to 6 meant uncertain, and 1 to 3 meant inappropriate. The panel rated the scenarios independently, then discussed the points of disagreement in a face-to-face meeting and by conference call before scoring them again in successive rounds. At the end of that process, the panel reached consensus on all 270 scenarios. The published split was 200 appropriate (74.07 percent), 24 uncertain (8.89 percent), and 46 inappropriate (17.04 percent).

The scenario matrix

The 270 scenarios are not a random list. They are the product of the variables that actually change the risk calculation, crossed against one another. The panel worked across four tumor groups: basal cell carcinoma, squamous cell carcinoma, lentigo maligna and melanoma in situ, and a set of rarer cutaneous malignancies. Each was then combined with the factors that raise or lower the stakes.

Location

The AUC divide the body into three zones. Area H is the highest-risk group: the central face and other mask areas, plus the genitalia, hands, feet, nail units, ankles, and the nipple and areola, all places where tissue is scarce and recurrence is costly. Area M covers the cheeks, forehead, scalp, neck, jawline, and shins. Area L is the lower-risk trunk and extremities, where a standard excision usually closes without difficulty.

Tumor and patient factors

Size, histologic subtype, and whether a tumor is new or recurrent all shift the rating, as does aggressive behavior such as an infiltrative or morpheaform growth pattern or perineural involvement. Patient characteristics matter too. Immunosuppression, certain genetic syndromes that predispose to many skin cancers, and a history of prior radiation to the site can all push a scenario toward appropriate, because the consequences of leaving cancer behind are higher.

What "appropriate" does and does not mean

Appropriate has a precise meaning here. The panel was told to rate a treatment as appropriate when its anticipated clinical benefit, combined with clinical judgment, exceeds its possible negative consequences for a specific indication. That is a comparative judgment, not a command. Appropriate is also not the same as necessary, a distinction the underlying method draws deliberately. The criteria do not specify which alternative treatment would be best when Mohs is rated uncertain or inappropriate. They are a starting point for a conversation, not a substitute for the clinical judgment that weighs an individual's health, preferences, and other options.

The AUC are also a living document. The developers anticipated revision as new evidence emerges, and later analyses have flagged scenarios where the ratings deserve a second look. That openness is a strength of the method rather than a weakness, because it keeps the reasoning explicit enough to be revisited. This article is educational and is not medical advice; treatment decisions belong with a qualified clinician who can examine the specific lesion.